Canaccord Genuity Maintains Buy on Bioventus, Raises Price Target to $19

Benzinga · 2d ago
Canaccord Genuity analyst Caitlin Cronin maintains Bioventus (NASDAQ:BVS) with a Buy and raises the price target from $15 to $19.